# Forty Seven

> Forty Seven turned Stanford research on the CD47 “don’t eat me” signal into a clinical-stage cancer company and a $4.9 billion sale to Gilead. Its lead antibody, magrolimab, ultimately failed pivotal tests; the company’s arc shows both the commercial power and clinical uncertainty of a compelling biological idea.

- **Founded:** 2015
- **Headquarters:** Menlo Park, United States
- **Founders:** Irving Weissman (Scientific cofounder), Ravindra Majeti (Scientific cofounder), Mark Chao (Scientific cofounder; clinical development), Jens-Peter Volkmer (Scientific cofounder; research)
- **Products:** Magrolimab (Hu5F9-G4; 5F9), FSI-174, FSI-189
- **Notable:** Advanced a Stanford CD47 discovery into human trials., Raised $75 million Series A and $75 million Series B rounds., Listed on Nasdaq as FTSV in 2018.

## Products & services

- **Magrolimab (Hu5F9-G4; 5F9)** — Investigational anti-CD47 monoclonal antibody studied alone and with cancer medicines including azacitidine and rituximab; development was discontinued after pivotal trial failures.
- **FSI-174** — Investigational anti-cKIT antibody studied as a proposed stem-cell-transplant conditioning regimen with magrolimab.
- **FSI-189** — Investigational anti-SIRPα antibody designed to act on the CD47 pathway.

## Achievements

- Advanced a Stanford CD47 discovery into human trials.
- Raised $75 million Series A and $75 million Series B rounds.
- Listed on Nasdaq as FTSV in 2018.
- Gilead acquired the company in 2020 in a transaction valued at about $4.9 billion.
- Gilead later discontinued magrolimab development; the 2025 EMA filing says no marketing authorization would be sought.

## Latest updates

- **2025-01** — Gilead told the European Medicines Agency it had discontinued further magrolimab development and did not plan marketing authorization in any indication.
- **2024-02** — Gilead stopped ENHANCE-3 after futility analysis and a higher observed incidence of Grade 5 serious adverse events; solid tumor enrollment was paused.
- **2023-07** — Gilead discontinued the Phase 3 ENHANCE MDS study for futility.

## Links

- Website: https://www.fortyseveninc.com
- LinkedIn: https://www.linkedin.com/company/forty-seven-inc-

---

Profile page: https://yespress.io/forty-seven
Published by YesPress — https://yespress.io
Last updated: 2026-09-29